Feed RPRX
RP

Royalty Pharma

RPRX · NASDAQ

$56.66 -0.87% (-$0.50)
1M -6.49%
Market Cap $25.1B
P/E Ratio 30.81x
Div. Yield 1.63%
ROE 12.25%

Bulios Fair Price

$41.14

27.4% downside

Trenutna cena

$56.66

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica RPRX trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Moderate
6/9
Valuation
48 /100
Fair
P/FCF 8.44x
P/E 30.81x
P/B 3.68x
Growth
57 /100
Stable
FCF growth 5.11%
EPS growth 162.07%
Book val. growth 4.79%
Profitability
100 /100
Strong
Op. margin 62.34%
Gross margin 89.38%
FCF margin 117.37%
Quality
43 /100
Average
ROA 4.11%
ROIC 8.08%
Asset turnover 0.13x
Debt
36 /100
Moderate
Int. coverage 4.74x
Debt/Equity 1.31x
Net debt/EBITDA 4.75x
Stability
59 /100
Moderate
EPS volatility 1,411.73%
Beta 0.43x
Profitable years 6

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RPRX
Online

O podjetju

Royalty Pharma plc is an international pharmaceutical company based in New York, USA, specializing in investments in royalty and licensing rights to pharmaceutical products. The company focuses on providing financial resources to research and development pharmaceutical companies in exchange for rights to profits from the sale of their drugs.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

CEO

Pablo Legorreta

Employees

100

Headquarters

New York

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

29d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.